Patent application number | Description | Published |
20090005459 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau - Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same. | 01-01-2009 |
20100029572 | Neurotrophic Peptides - The present invention relates to a neurotrophic peptide having an amino acid sequence selected from the group consisting of VG-DGGLFEKKL (SEQ ID No. 1), EDQQVHFTPTEG (SEQ ID No. 2) and IPENEADGMPATV (SEQ ID NO. 3). | 02-04-2010 |
20100273196 | System and Method for Evaluating Blood-Neural Barrier Permeability - A system and method for evaluating blood-neural barrier permeability. Phospholipid liposomes are labeled with a fluorescent phospholipase A | 10-28-2010 |
20110160141 | Neurotrophic Peptides - The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1), EDQQVHFTPTEG (SEQ ID NO:2) or IPENEADGMPATV (SEQ ID NO:3), and comprising an adamantyl group at the C- and/or N-terminal end. | 06-30-2011 |
20120157537 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau - Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same. | 06-21-2012 |
20130143809 | NEUROTROPHIC PEPTIDES - The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Down syndrome. | 06-06-2013 |
20130157946 | NEUROTROPHIC PEPTIDES - The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Alzheimer's disease. | 06-20-2013 |
20140018294 | NEUROGENIC BRAIN-DERIVED NEUROTROPHIC FACTOR PEPTIDES - Five tetra peptides corresponding to different active regions of brain derived neurotrophic factor (BDNF) that are neurotrophic and can modulate BDNF signaling in a partial agonist/antagonist way. The peptides offer a therapeutic approach to neural pathologies where BDNF levels are dysregulated. | 01-16-2014 |
20140357572 | NEUROTROPHIC PEPTIDES FOR THE TREATMENT OF TAUOPATHIES - Peptide 6 and in particular, Peptide 021, may be used to treat tauopathies, such as frontotemporal dementia with Parkinsonism linked to chromosome-17 (FTDP-17) tau, corticobasal degeneration, Pick disease, progressive supranuclear palsy, Guam Parkinsonism dementia complex, dementia pugilistica also known as traumatic encephalopathy or traumatic brain injury, ceroid neuronal lipofusinosis, Hallerworden Sptaz disease, Alzheimer's disease, and adults with Down syndrome. | 12-04-2014 |